| name | endo-preop-srl-severe-pharyngeal-sleepapnea-hf |
| description | This skill suggests preoperative somatostatin receptor ligand (SRL) therapy to reduce anesthetic risk in acromegaly patients with severe pharyngeal thickness, obstructive sleep apnea, or high-output heart failure. It is triggered when assessing preoperative risk before transsphenoidal surgery and phrases like "severe pharyngeal thickening", "sleep apnea syndrome", or "high-output heart failure" are identified. |
Preoperative SRL for severe pharyngeal thickness, sleep apnea, or high-output heart failure
STEP 1 — Gather Information
Collect data on pharyngeal thickness (Mallampati grade ≥3, neck circumference >40 cm, or imaging showing narrowing), sleep apnea (STOP‑BANG ≥5 or polysomnography AHI >15), high‑output heart failure (cardiac index >4 L/min/m², dyspnea at rest, edema, echocardiogram showing elevated output), and confirm acromegaly (elevated IGF‑1 with lack of GH suppression). Document planned transsphenoidal surgery date.
STEP 2 — Rule In / Rule Out
If any of severe pharyngeal thickness, sleep apnea, or high‑output heart failure is present → proceed to Step 3; if none are present → follow routine preoperative optimization (no SRL indicated).
STEP 3 — Classify or Stratify
Classify as candidate for preoperative SRL therapy. Obtain baseline liver function tests, fasting glucose, and consider gallbladder ultrasound only if symptomatic. Choose SRL agent: octreotide LAR or lanreotide autogel.
STEP 4 — Decide
Initiate SRL at standard starting dose (octreotide LAR 20 mg IM monthly or lanreotide autogel 90 mg SC monthly) for 4–6 weeks preoperatively. Reassess pharyngeal symptoms, sleep apnea scores, and cardiac status; continue postoperatively if biochemical control is needed per guideline 5.1.
Clinical Guardrails / Mimics / Pitfalls
Do not use SRL solely to improve IGF‑1 levels without the comorbid indication (see 4.3). Avoid in patients with known SRL allergy, uncontrolled GI obstruction, or active infection. Monitor for hyperglycemia, gallstones, and injection‑site reactions. Do not delay urgent surgery for prolonged SRL course; a minimum of 2–4 weeks may still confer benefit.
Concrete Clinical Example
A 50‑year‑old with acromegaly, macroadenoma abutting the cavernous sinus, Mallampati grade 4, diagnosed OSA (AHI 28), and high‑output heart failure (cardiac index 4.8 L/min/m²) scheduled for transsphenoidal decompression; started lanreotide autogel 90 mg monthly for 6 weeks preoperatively, resulting in reduced snoring, improved dyspnea, and uneventful intubation.
Source: Acromegaly: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2014, DOI:10.1210/jc.2014-2700
